Patients must have disease that is not amenable to potentially curative resection or ablative techniques or that has recurred following ablative techniques. In addition, disease must not be amenable to transhepatic arterial chemoembolization (TACE) or must have progressed on TACE. Patients must not be candidates for liver transplantation.
Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy
Not a candidate for potentially curative therapy at the time of enrollment
Participants must have histologically confirmed adenoid cystic carcinoma with evidence of recurrent or metastatic disease not amenable to potentially curative surgery or radiotherapy
Has a known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
Subjects with tumor amenable to potentially curative therapy per principal investigator (PI)
Be eligible and reasonably fit to undergo potentially curative resection
Patients must have disease that is not amenable to potentially curative resection
Patients must have disease that is not amenable to potentially curative resection
Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
Subjects not seeking or receiving potentially curative therapies for cancer.
Ability to undergo potentially curative chemotherapy plus radiotherapy
Patients must have disease that is not amenable to potentially curative resection; patients must have received, been intolerant of or refused at least one line of chemotherapy
Patient's cancer must have relapsed after or failed to respond to frontline curative therapy or there must not be other potentially curative treatment options available
Patients must have disease that is not amenable to potentially curative resection, transplantation or ablation; HCC patients must have progressed on, been intolerant to, or refused prior sorafenib therapy; patients with BTC must have received, been intolerant of or refused at least one line of chemotherapy
Patients must have potentially curable disease
Patients with a history of a prior malignancy who have undergone potentially curative therapy with no evidence of that disease for five years, or patients who are deemed low risk for recurrence by his/her treating physician are permitted to enroll
Subjects with tumor amenable to potentially curative therapy
Candidate for known standard therapy for the patient’s disease that is potentially curative
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy; subjects will be excluded if this is their first relapse and they have recurred > 6 months from completion of primary (adjuvant) chemotherapy
Must not be a candidate for potentially curative therapy or standard-of-care approved therapy
Histologically or cytologically confirmed, or clinically diagnosed based on currently accepted standards, cancer metastatic to the liver or HCC that is not amenable at the time of enrollment to resection, transplant or other potentially curative therapy.
Primary HCC amenable to resection, transplant or other potentially curative therapy.
Received and failed potentially curative chemotherapeutic regimens (e.g., ABVD, Stanford V, or BEACOPP)
Must not be a candidate for potentially curative therapy or standard-of-care approved therapy.
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy
Known standard therapy for the patient’s disease that is potentially curative
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy; EXCEPTION: For platinum-resistant ovarian cancer, because nab-paclitaxel has known benefit, patients who may benefit from standard single agent chemotherapy are also eligible to participate
COHORT I (DOSE ESCALATION): known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy
Patients who are candidates (eligible and willing) for standard and/or potentially curative treatments are not eligible
Patients who have received prior chemoradiation, radiation, and/or surgery in the potentially curative setting are eligible as long as 3 months has elapsed since the end of the potentially curative treatment ended
Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy
Have no curative therapy available.
Subjects for whom potentially curative anticancer therapy is available.
Patients must have disease that is not amenable to potentially curative resection, and must not have metastatic disease
Patients must have recurrent and/or metastatic disease not amenable to potentially curative surgery or radiotherapy
Known standard therapy for the patient’s disease that is potentially curative
Patients must have no known curative therapy available
The patient has undergone potentially curative therapy for all prior malignancies,
Received one or more lines of chemotherapy, which must include prior treatment with a platinum agent and must not be amenable to potentially curative radiotherapy or surgery
Known standard therapy for the patient’s disease that is potentially curative or proven capable of extending life expectancy
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy
Patients who have recurrences that are amenable to potentially curative treatment with radiation therapy or surgery
Patients must have recurrent and/or metastatic disease not amenable to potentially curative surgery or radiotherapy
Subjects for whom potentially curative anticancer therapy is available.
Disease eligible for potentially curative treatment with standard chemotherapy, surgical resection, or chemoradiotherapy
Subjects for whom potentially curative anticancer therapy is available.
Candidate for potentially curative therapies in the opinion of the investigator.
Patients must have disease that is not amenable to potentially curative resection, transplantation or ablation; for Cohorts A and D patients must have progressed on, been intolerant to, or refused prior sorafenib therapy; Cohort E patients must have received at least one line of chemotherapy for BTC
Patients with isolated recurrences (vaginal, pelvic, or para-aortic) that are amenable to potentially curative treatment with radiation therapy or surgery
Patients with tumor amenable to potentially curative therapy
Potentially curative therapy is available
Known standard therapy for the patient’s disease that is potentially curative or proven capable of extending life expectancy
Patients for whom potentially curative anticancer therapy is available
Candidate for known standard therapy for the patient’s disease that is potentially curative
Patients must have recurrent and/or metastatic disease not amenable to potentially curative surgery or radiotherapy
Liver disease must not be amenable to potentially curative surgical resection
Patients must have disease that is potentially amenable to curative resection as reviewed by the Medical University of South Carolina (MUSC) Gastrointestinal (GI) Tumor Board
Patients must have disease that is potentially amenable to curative resection as reviewed by the Medical University of South Carolina (MUSC) Gastrointestinal (GI) Tumor Board
Patients with tumor amenable to potentially curative therapy as assessed by the investigator
Patients with tumor amenable to potentially curative therapy as assessed by the investigator
Patients who have isolated recurrences (vaginal, pelvic, or paraaortic) that are amenable to potentially curative treatment with radiation therapy or surgery
Subjects for whom potentially curative anticancer therapy is available
Subject is eligible for a potentially curative therapy.
Histologically or cytologically confirmed mCRC not amenable to potentially curative resection with at least one measurable metastatic lesion, as defined by RECIST v1.1
Subjects must have failed, be intolerant to, or be ineligible for any potentially curative approved treatment, irrespective of line of therapy
The subject had at least one prior line of systemic therapy and has a tumor, which is not amenable to potentially curative surgical resection.
Patients for whom potentially curative antineoplastic therapy is available
Patients must have disease that is not amenable to potentially curative resection or ablative techniques; in addition, disease must not be amenable to or have progressed on transhepatic arterial chemoembolization (TACE); patients must not be considered potential candidates for liver transplantation; this determination will be made after hepatobiliary surgical input at the NCI multidisciplinary conference
Patients with cancer potentially curable by surgical excision alone or patients who have not received therapy that might be considered standard and potentially curable
Be eligible and reasonably fit to undergo potentially curative resection
For patients with lymphomas that are considered potentially curable, all curative attempts should be exhausted before the patient is considered eligible for this study
If the patient is a survivor of a prior invasive cancer, all of the following criteria must apply: \r\n* Patient has undergone potentially curative therapy for all prior malignancies\r\n* No evidence of active/recurrent disease